Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 36(23): 3646-57, 1993 Nov 12.
Artigo em Inglês | MEDLINE | ID: mdl-8246233

RESUMO

3,5-Dihydroxy-7-(N-imidazolyl)heptanoates 4 and the corresponding heptenoates 5 were synthesized as novel classes of potent HMG-CoA reductase (HMGR) inhibitors in which members of the latter series possess enzyme inhibitory activity greater than that of lovastatin 1 and pravastatin 2. Structure-activity studies show that the 7-(N-imidazolyl)heptenoates 5 are more active than the corresponding heptanoates 4. For both imidazolyl series, the 4-fluorophenyl group is preferred at C-5, and a broad range of aryl substituents which promote widely different lipophilicities is tolerated at C-4. While the CF3 group is preferred at C-2 in the heptanoate series, the 2-(1-methylethyl) substituent is optimal in the heptenoate series. The 2-(1-methylethyl) and 5-(4-fluorophenyl) groups can be interchanged in the latter series as exemplified by 5ab. Enzyme inhibitory activity resides principally in the 3R,5S series. These potent HMGR inhibitory activities by members of the heptenoate series translated well into whole cell activities in HepG2 cells. X-ray crystallographic studies on the active enantiomer 28 reveal noncoplanarity of the heptenoate C-C double bond with the imidazole ring; this finding provides an explanation for the high acid stability of the heptenoate series.


Assuntos
Colesterol/biossíntese , Heptanoatos/síntese química , Hidroxiácidos/síntese química , Inibidores de Hidroximetilglutaril-CoA Redutases , Imidazóis/síntese química , Animais , Cristalografia por Raios X , Heptanoatos/farmacologia , Hidroxiácidos/farmacologia , Imidazóis/farmacologia , Lovastatina/farmacologia , Microssomos Hepáticos/enzimologia , Estrutura Molecular , Pravastatina/farmacologia , Ratos
2.
J Med Chem ; 36(24): 3784-94, 1993 Nov 26.
Artigo em Inglês | MEDLINE | ID: mdl-7504733

RESUMO

A series of substituted imidazo[1,5-b]pyridazines have been prepared and tested for inhibitory activity against the reverse transcriptase of HIV-1 (RT) and their ability to inhibit the growth of infected MT-4 cells. Crystal data are reported on two compounds, 15c and 33. From the structure-activity relationships developed within this and other series, it is proposed that key features of the interaction with RT include hydrogen-bond acceptor and aromatic pi-orbital bonding with the imidazopyridazine nucleus and a benzoyl function separated from the heterocycle by a suitable spacer group. Exceptional activity against the reverse transcriptase of HIV-1 (IC50 = 0.65 nM) was obtained with a 2-imidazolyl-substituted derivative, 7-[2-(1H-imidazol-1- yl)-5-methylimidazo-[1,5-b]pyridazin-7-yl]-1-phenyl-1-heptanone (33) which is attributed to additional binding of the imidazole sp2 nitrogen atom. A number of the compounds in this series also inhibit the replication of HIV-1 in vitro in MT-4 and C8166 cells at levels observed with the nucleoside AZT.


Assuntos
Antivirais/farmacologia , HIV-1/efeitos dos fármacos , Imidazóis/síntese química , Piridazinas/síntese química , Inibidores da Transcriptase Reversa , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Cristalização , Transcriptase Reversa do HIV , HIV-1/enzimologia , Imidazóis/farmacologia , Estrutura Molecular , Piridazinas/farmacologia , Relação Estrutura-Atividade , Replicação Viral/efeitos dos fármacos , Zidovudina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...